Alnylam Pharmaceuticals (ALNY) Invested Capital (2016 - 2025)
Historic Invested Capital for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $789.2 million.
- Alnylam Pharmaceuticals' Invested Capital rose 39051.27% to $789.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $789.2 million, marking a year-over-year increase of 39051.27%. This contributed to the annual value of $789.2 million for FY2025, which is 39051.27% up from last year.
- Latest data reveals that Alnylam Pharmaceuticals reported Invested Capital of $789.2 million as of Q4 2025, which was up 39051.27% from $355.2 million recorded in Q3 2025.
- Alnylam Pharmaceuticals' 5-year Invested Capital high stood at $1.3 billion for Q2 2021, and its period low was -$408.1 million during Q2 2023.
- Over the past 5 years, Alnylam Pharmaceuticals' median Invested Capital value was $197.2 million (recorded in 2024), while the average stood at $361.5 million.
- In the last 5 years, Alnylam Pharmaceuticals' Invested Capital tumbled by 14780.38% in 2023 and then surged by 1220925.99% in 2025.
- Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Invested Capital stood at $1.3 billion in 2021, then plummeted by 112.52% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then surged by 172.92% to $160.9 million in 2024, then skyrocketed by 390.51% to $789.2 million in 2025.
- Its Invested Capital was $789.2 million in Q4 2025, compared to $355.2 million in Q3 2025 and $371.4 million in Q2 2025.